Fassina A, Corradin M, Zardo D, Cappellesso R, Corbetti F, Fassan M
Department of Diagnostic Medical Sciences and Special Therapies, Surgical Pathology and Cytopathology Unit, University of Padova, Via Gabelli 61, Padua, Italy.
Cytopathology. 2011 Oct;22(5):306-12. doi: 10.1111/j.1365-2303.2010.00802.x. Epub 2010 Aug 25.
To prospectively investigate the role of trans-thoracic fine needle aspiration cytology (FNA) and the value of rapid on-site evaluation (ROSE) in the clinical management of patients with pulmonary nodules/masses. Computed tomography (CT)-guided FNA is commonly employed for the diagnosis of lung lesions although its position in the diagnostic work-up is still a matter of debate.
We reviewed 311 patients (211 males and 100 females, mean age 69.5 years) admitted to the University of Padova from 2004 to 2008, correlating the results of cytology with the available histological findings obtained from biopsies, surgery or autopsy.
Smears were adequate in 305 cases (98%) and inadequate in six (2%); a diagnosis of malignancy was achieved in 263 cases (86.2%); 39 cases (12.8%) were classified as non-malignant; and three cases (1%) were classified as suspect for malignancy. When correlated with histology, FNA with ROSE discriminated malignant versus non-malignant lesions (Cohen's kappa 0.78), with three false negatives (sensitivity 96.3%, specificity 100%). Moreover, a satisfactory overall agreement of 71.4% was achieved in differentiating the cancer histological types. Pneumothorax occurred in 13 cases, haemoptysis in four, and chest pain in three. A single aspiration was sufficient in 79.6% of patients; two aspirations were needed in 17.4% and three in 3%. The low complication rate was related to the limited number of aspirations needed due to ROSE.
FNA with ROSE is a safe and useful tool in the diagnostic work-up of lung cancer patients, with no contraindications to its use as the first diagnostic procedure for all patients with peripheral lung lesions. FNA with ROSE should be reconsidered in the guidelines for diagnosing and managing lung cancer.
前瞻性研究经胸细针穿刺细胞学检查(FNA)及快速现场评估(ROSE)在肺结节/肿块患者临床管理中的作用。计算机断层扫描(CT)引导下的FNA常用于肺病变的诊断,但其在诊断流程中的地位仍存在争议。
我们回顾了2004年至2008年帕多瓦大学收治的311例患者(男性211例,女性100例,平均年龄69.5岁),将细胞学检查结果与通过活检、手术或尸检获得的组织学结果进行关联。
305例(98%)涂片合格,6例(2%)不合格;263例(86.2%)诊断为恶性;39例(12.8%)分类为非恶性;3例(1%)分类为疑似恶性。与组织学结果相关分析时,FNA联合ROSE可区分恶性与非恶性病变(科恩kappa系数为0.78),有3例假阴性(敏感性96.3%,特异性100%)。此外,在区分癌症组织学类型方面,总体一致性令人满意,为71.4%。发生气胸13例,咯血4例,胸痛3例。79.6%的患者一次穿刺就足够;17.4%的患者需要两次穿刺,3%的患者需要三次穿刺。并发症发生率低与因ROSE所需穿刺次数有限有关。
FNA联合ROSE是肺癌患者诊断检查中的一种安全且有用的工具,对于所有周围型肺病变患者,作为首选诊断程序使用无禁忌证。在肺癌诊断和管理指南中应重新考虑FNA联合ROSE。